Update on Gastroesophageal Adenocarcinoma Targeted Therapies.

about

Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.The dynamics of HER2 status in esophageal adenocarcinoma.

P2860

Q47864236-AA69050D-9FAB-40C2-9D88-6D5421AA543A Q55290336-ADAACF6B-0A4D-45CE-B196-E584495EA0AC

P2860

Update on Gastroesophageal Adenocarcinoma Targeted Therapies.

Item

http://www.wikidata.org/entity/Q38684349

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Update on Gastroesophageal Adenocarcinoma Targeted Therapies.

@en

type

Item

label

Update on Gastroesophageal Adenocarcinoma Targeted Therapies.

@en

prefLabel

Update on Gastroesophageal Adenocarcinoma Targeted Therapies.

@en

P1476

Update on Gastroesophageal Adenocarcinoma Targeted Therapies.

@en

P2093

Daniel V T Catenacci

http://www.w3.org/2001/XMLSchema#string

Steven B Maron

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity

Signaling cross-talk in the resistance to HER family receptor targeted therapy

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Global cancer statistics, 2012

Cancer statistics, 2015

Comprehensive molecular characterization of gastric adenocarcinoma

P304

511-527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.HOC.2017.01.009

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28501091

http://www.w3.org/2001/XMLSchema#string

P932

5446061

http://www.w3.org/2001/XMLSchema#string

Update on Gastroesophageal Adenocarcinoma Targeted Therapies.

about

P2860

P2860

Update on Gastroesophageal Adenocarcinoma Targeted Therapies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932